← Eichor
Study identifier: NCT06791525 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Tirbanibulin for Pediatric Warts

Condition: Warts Hand  ·  Sponsor: The Skin Center Dermatology Group

PhasePhase 4
Planned participants10
Who can joinAll sexes, 8 Years to 18 Years
Healthy volunteersNo

About this study

Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.

This description comes directly from the study's public registry record.

Talk to the study team

Peter Friedman, MD, PhD  ·  8453520500  ·  drfriedman@skincenterderm.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Skin Center Dermatology GroupNew City, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06791525